Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy

<p>Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by deficient estroge...

Full description

Saved in:
Bibliographic Details
Main Authors: Tze-Chen Hsieh (Author), Joseph M Wu (Author)
Format: Book
Published: International Journal of Immunotherapy and Cancer Research - Peertechz Publications, 2020-07-18.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 peertech__10_17352_2455-8591_000024
042 |a dc 
100 1 0 |a Tze-Chen Hsieh  |e author 
700 1 0 |a Joseph M Wu  |e author 
245 0 0 |a Novel insights on use of doxorubicin to treat chemoresistant TNBC by Immunotherapy 
260 |b International Journal of Immunotherapy and Cancer Research - Peertechz Publications,   |c 2020-07-18. 
520 |a <p>Doxorubicin, a WHO listed essential medicine, is used primarily as a combination of taxane/ anthracycline (doxorubicin)/cyclophosphamide (TAC), for treating malignant diseases including triple-negative breast cancer (TNBC). TNBC is a subtype of breast cancer categorized by deficient estrogen receptor, progesterone receptor, and epidermal growth factor receptor HER-2 [1]. TNBC is challenging to treat due to its genotype and phenotype heterogeneity [2-5], aggressiveness, recurrence [6-10], and resistance to existing therapies. Roughly, 25-45% TNBC patients receiving TAC as preoperative therapy achieve complete response and excellent long-term prognosis [11], while patients who fail TAC have poor prognosis and few therapeutic choices [2].</p> 
540 |a Copyright © Tze-Chen Hsieh et al. 
546 |a en 
655 7 |a Mini Review  |2 local 
856 4 1 |u https://doi.org/10.17352/2455-8591.000024  |z Connect to this object online.